SAN FRANCISCO, May 04, 2020 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, today announced the appointment of Noreen R. Henig, MD as its Chief Medical Officer. As an integral… Read More..

SGX301 treatment response continues to demonstrate highly statistically significant improvement after 12 weeks of therapy Response rate in patients receiving a total of 12 weeks treatment increased two and a half-fold Reinforces positive SGX301 primary endpoint treatment response demonstrating statistical significance after 6 weeks of therapy Princeton, NJ – April 30, 2020… Read More..

NEW YORK, April 28, 2020 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications, today announced that it has released its annual letter to shareholders. In… Read More..